BioXcel Therapeutics Inc Cash Flow-to-Debt Ratio
BioXcel Therapeutics Inc cash flow-to-debt ratio. BioXcel Therapeutics Inc (BTAI) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2026, meaning its operating cash flow of $-6.10 Million could theoretically repay 0% of its total liabilities ($144.26 Million) in one year. See financial flexibility index of BioXcel Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BioXcel Therapeutics Inc (2015–2025)
Cash flow-to-debt ratio of BioXcel Therapeutics Inc from 2015 to 2025. Historical debt coverage capacity for BioXcel Therapeutics Inc across 11 annual periods. Also explore BioXcel Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
BioXcel Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
BioXcel Therapeutics Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for BioXcel Therapeutics Inc. For the full cash flow conversion analysis, see BioXcel Therapeutics Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.41x | $-57.62 Million | $140.38 Million | ▲ +25.1% |
| 2024 | -0.55x | $-72.03 Million | $131.44 Million | ▲ +54.0% |
| 2023 | -1.19x | $-155.01 Million | $130.21 Million | ▼ -13.5% |
| 2022 | -1.05x | $-135.34 Million | $129.08 Million | ▲ +77.3% |
| 2021 | -4.62x | $-82.15 Million | $17.77 Million | ▲ +7.8% |
| 2020 | -5.01x | $-66.35 Million | $13.24 Million | ▼ -74.5% |
| 2019 | -2.87x | $-27.28 Million | $9.50 Million | ▲ +0.9% |
| 2018 | -2.90x | $-13.51 Million | $4.66 Million | ▼ -208.5% |
| 2017 | -0.94x | $-2.20 Million | $2.34 Million | ▲ +76.0% |
| 2016 | -3.91x | $-1.29 Million | $331.00K | ▼ -144.3% |
| 2015 | -1.60x | $-280.00K | $175.00K | — |